Kistler Tiffany Companies LLC reduced its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 9.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,467 shares of the biopharmaceutical company’s stock after selling 1,220 shares during the quarter. Kistler Tiffany Companies LLC’s holdings in Bristol-Myers Squibb were worth $596,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the stock. Carroll Financial Associates Inc. raised its position in shares of Bristol-Myers Squibb by 1.5% in the 4th quarter. Carroll Financial Associates Inc. now owns 17,024 shares of the biopharmaceutical company’s stock valued at $824,000 after purchasing an additional 248 shares during the last quarter. Arlington Partners LLC raised its position in shares of Bristol-Myers Squibb by 40.0% in the 4th quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 400 shares during the last quarter. Curbstone Financial Management Corp raised its position in shares of Bristol-Myers Squibb by 4.6% in the 4th quarter. Curbstone Financial Management Corp now owns 12,542 shares of the biopharmaceutical company’s stock valued at $652,000 after purchasing an additional 550 shares during the last quarter. Wealth Architects LLC raised its position in shares of Bristol-Myers Squibb by 14.0% in the 3rd quarter. Wealth Architects LLC now owns 6,923 shares of the biopharmaceutical company’s stock valued at $430,000 after purchasing an additional 848 shares during the last quarter. Finally, Beech Hill Advisors Inc. raised its position in Bristol-Myers Squibb by 0.8% during the 3rd quarter. Beech Hill Advisors Inc. now owns 105,500 shares of the biopharmaceutical company’s stock worth $6,549,000 after buying an additional 850 shares during the last quarter. 72.68% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have issued reports on BMY shares. Barclays raised their price target on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Friday, October 12th. Morgan Stanley reduced their price target on shares of Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, November 6th. Credit Suisse Group reissued a “hold” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a research report on Thursday, December 13th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price target for the company in a research report on Friday, October 5th. Finally, ValuEngine lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $61.56.
Shares of NYSE BMY traded down $0.04 during midday trading on Monday, reaching $47.95. 400,969 shares of the stock were exchanged, compared to its average volume of 29,582,822. The stock has a market capitalization of $77.01 billion, a price-to-earnings ratio of 15.95, a PEG ratio of 1.29 and a beta of 0.98. Bristol-Myers Squibb Co has a twelve month low of $44.30 and a twelve month high of $70.05. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.18. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. Analysts anticipate that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 1st. Stockholders of record on Friday, January 4th will be paid a dividend of $0.41 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.42%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 54.49%.
TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb Co (BMY) Shares Sold by Kistler Tiffany Companies LLC” was originally posted by Zolmax and is owned by of Zolmax. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://zolmax.com/investing/bristol-myers-squibb-co-bmy-shares-sold-by-kistler-tiffany-companies-llc/2824291.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: Google Finance Portfolio Workaround
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.